Akero Therapeutics, a clinical-stage company based in South San Francisco, California, is committed to developing innovative treatments for patients with serious metabolic diseases that have high unmet medical needs. The company recently announced that its management will be presenting at the BofA Securities 2024 Health Care Conference on May 14, 2024, at 5:00 p.m. Pacific Time in Las Vegas, Nevada. Interested parties can tune into a live webcast of the presentation on the investor relations section of Akero Therapeutics’ website,
Currently, Akero Therapeutics is focusing on developing treatments for metabolic diseases such as MASH. The company’s lead product candidate, EFX, is undergoing evaluation in the SYMMETRY study, a Phase 2b clinical trial lasting 96 weeks for patients with compensated cirrhosis due to MASH (F4 fibrosis). Additionally, Akero Therapeutics has two ongoing Phase 3 clinical trials: the SYNCHRONY Histology study for patients with pre-cirrhotic MASH (F2-F3 fibrosis) and the SYNCHRONY Real-World study for patients with MASH (F1-F3 fibrosis) or MASLD. Another Phase 3 clinical trial, the SYNCHRONY Outcomes study for patients with compensated cirrhosis due to MASH (F4 fibrosis), is scheduled to begin in the second quarter of 2024. These studies build upon the positive results of the HARMONY and SYMMETRY Phase 2b clinical trials.
For investors looking to get in touch with Akero Therapeutics, they can reach out to Christina Tartaglia of Stern Investor Relations at [(212) 362-1200](ntouch://call/+1%28212%29%20362-1200 “Call Christina Tartaglia at +1 (